Fresolimumab Biosimilar – Anti-TGFB, TGF beta mAb – Research Grade from ProteoGenix; catalogue PX-TA1128; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Fresolimumab Biosimilar, also known as Anti-TGFB or TGF beta mAb, is a monoclonal antibody that targets the transforming growth factor beta (TGF-beta) protein. It is a research grade antibody with potential therapeutic applications in various diseases. In this article, we will discuss the structure, activity, and potential applications of Fresolimumab Biosimilar.
Fresolimumab Biosimilar is a fully human monoclonal antibody that is produced using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the target protein, while the Fc region mediates effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Fresolimumab Biosimilar specifically targets the active form of TGF-beta, which is a multifunctional cytokine involved in various cellular processes such as cell growth, differentiation, and immune response. TGF-beta plays a crucial role in tissue repair and regeneration, but its dysregulation has been linked to the development of many diseases, including cancer, fibrosis, and autoimmune disorders. Fresolimumab Biosimilar binds to TGF-beta with high affinity and blocks its interaction with its receptors, thereby inhibiting its downstream signaling pathways.
1.
TGF-beta has been shown to promote tumor growth, invasion, and metastasis in various types of cancer. By blocking TGF-beta signaling, Fresolimumab Biosimilar has the potential to inhibit tumor growth and metastasis. In preclinical studies, it has shown promising results in suppressing the growth of breast, lung, and pancreatic tumors. Clinical trials are currently underway to evaluate the efficacy of Fresolimumab Biosimilar in combination with other cancer therapies.
2. Fibrotic Diseases Fibrosis is a common pathological process characterized by excessive deposition of extracellular matrix, leading to tissue scarring and organ dysfunction. TGF-beta is a key mediator of fibrosis, and its inhibition has been shown to prevent and reverse fibrosis in various organs, including the liver, lungs, and kidneys. Fresolimumab Biosimilar has shown efficacy in preclinical models of fibrotic diseases, and clinical trials are ongoing to evaluate its potential as a treatment for conditions such as idiopathic pulmonary fibrosis and systemic sclerosis.
3.
TGF-beta is known to play a role in regulating the immune response, and its dysregulation has been linked to the development of autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. By blocking TGF-beta signaling, Fresolimumab Biosimilar has the potential to modulate the immune response and reduce inflammation in these conditions. Clinical trials are currently underway to evaluate its efficacy in treating autoimmune disorders.
4. Wound Healing TGF-beta plays a crucial role in wound healing by promoting the formation of new blood vessels and stimulating the production of extracellular matrix. However, excessive TGF-beta signaling can lead to excessive scarring and impaired wound healing. Fresolimumab Biosimilar has shown promise in promoting wound healing in preclinical studies and is currently being evaluated in clinical trials for the treatment of diabetic foot ulcers.
Fresolimumab Biosimilar, a research grade antibody that targets TGF-beta, has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various diseases. Its unique mechanism of action makes it a potential therapeutic option for cancer, fibrotic diseases, autoimmune disorders, and wound healing. Further research and clinical trials will provide more insights into the efficacy and safety of this antibody and its potential as a treatment for these conditions.
ProteoGenix catalogue number PX-TA1128. For research use only.
Target: Fresolimumab Biosimilar – Anti-TGFB, TGF beta mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Fresolimumab Biosimilar – Anti-TGFB, TGF beta mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
